» Articles » PMID: 25681614

Novel GAA Mutations in Patients with Pompe Disease

Abstract

Pompe disease is an autosomal recessive disorder linked to GAA gene that leads to a multi-system intralysosomal accumulation of glycogen. Mutation identification in the GAA gene can be very important for early diagnosis, correlation between genotype-phenotype and therapeutic intervention. For this purpose, peripheral blood from 57 individuals susceptible to Pompe disease was collected and all exons of GAA gene were amplified; the sequences and the mutations were analyzed in silico to predict possible impact on the structure and function of the human protein. In this study, 46 individuals presented 33 alterations in the GAA gene sequence, among which five (c.547-67C>G, c.547-39T>G, p.R437H, p.L641V and p.L705P) have not been previously described in the literature. The alterations in the coding region included 15 missense mutations, three nonsense mutations and one deletion. One insertion and other 13 single base changes were found in the non-coding region. The mutation p.G611D was found in homozygosis in a one-year-old child, who presented low levels of GAA activity, hypotonia and hypertrophic cardiomyopathy. Two patients presented the new mutation p.L705P in association with c.-32-13T>G. They had low levels of GAA activity and developed late onset Pompe disease. In our study, we observed alterations in the GAA gene originating from Asians, African-Americans and Caucasians, highlighting the high heterogeneity of the Brazilian population. Considering that Pompe disease studies are not very common in Brazil, this study will help to better understand the potential pathogenic role of each change in the GAA gene. Furthermore, a precise and early molecular analysis improves genetic counseling besides allowing for a more efficient treatment in potential candidates.

Citing Articles

Highlights of Precision Medicine, Genetics, Epigenetics and Artificial Intelligence in Pompe Disease.

Moschetti M, Venezia M, Giacomarra M, Marsana E, Zizzo C, Duro G Int J Mol Sci. 2025; 26(2).

PMID: 39859472 PMC: 11766448. DOI: 10.3390/ijms26020757.


Mutation Spectrum of Gene in Pompe Disease: Current Knowledge and Results of an Italian Study.

Moschetti M, Lo Curto A, Giacomarra M, Francofonte D, Zizzo C, Messina E Int J Mol Sci. 2024; 25(17).

PMID: 39273088 PMC: 11394944. DOI: 10.3390/ijms25179139.


Carrier screening for present disease prevalence and recessive genetic disorder in Taiwanese population.

Chen L, Yu C, Li W, Hsieh W, Li Y J Hum Genet. 2023; 69(3-4):115-118.

PMID: 38135707 DOI: 10.1038/s10038-023-01212-7.


An artificial intelligence-based approach for identifying rare disease patients using retrospective electronic health records applied for Pompe disease.

Lin S, Nateqi J, Weingartner-Ortner R, Gruarin S, Marling H, Pilgram V Front Neurol. 2023; 14:1108222.

PMID: 37153672 PMC: 10160659. DOI: 10.3389/fneur.2023.1108222.


Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants.

Limgala R, Furtak V, Ivanova M, Changsila E, Wilks F, Fidelia-Lambert M JIMD Rep. 2021; 59(1):60-68.

PMID: 33977031 PMC: 8100401. DOI: 10.1002/jmd2.12201.